<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04835675</url>
  </required_header>
  <id_info>
    <org_study_id>ZJYY-2020006</org_study_id>
    <nct_id>NCT04835675</nct_id>
  </id_info>
  <brief_title>AssesSment of Early-deteCtion basEd oN liquiD Biopsy in Hepatobiliary Cancer Malignancies</brief_title>
  <acronym>ASCEND-Hep</acronym>
  <official_title>Development and Validation of the Performance of a cfDNA Methylation-based Model Combined With Serum Tumor Markers for Early Hepatobiliary Malignancies Detection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhujiang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Guangzhou BR</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Zhujiang Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a prospective, multicenter study aimed to develop and validate the performance&#xD;
      of combined assays for cfDNA methylation markers and serum tumor markers in early&#xD;
      hepatobiliary malignancies detection. Circulating tumor DNA (ctDNA) mutation, blood RNA&#xD;
      markers and tissue will also be evaluated. The study will enroll approximately 496&#xD;
      participants, including participants with malignant or benign diseases of the hepatobiliary&#xD;
      system.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 12, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity of early hepatobiliary malignancies detection and Tissue of origin (TOO) accuracy of a cfDNA methylation-based model combined with serum tumor markers when specificity was 90%, 95% or 98%</measure>
    <time_frame>16 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Sensitivity and specificity of early hepatobiliary malignancies detection and TOO accuracy of a cfDNA methylation-based model combined with serum tumor markers</measure>
    <time_frame>16 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sensitivity and specificity of a cfDNA methylation-based model combined with serum tumor markers in early detection of hepatobiliary malignancies in different stages</measure>
    <time_frame>16 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensitivity and specificity of a cfDNA methylation-based model combined with serum tumor markers, clinical characteristics and other biomarkers</measure>
    <time_frame>16 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensitivity and specificity of a cfDNA methylation-based model combined with serum tumor markers in participants with malignant or benign diseases of the hepatobiliary system</measure>
    <time_frame>16 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensitivity and specificity of a cfDNA methylation-based model or serum tumor markers in participants with hepatobiliary malignancies</measure>
    <time_frame>16 months</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">496</enrollment>
  <condition>Hepatobiliary Malignancies</condition>
  <arm_group>
    <arm_group_label>Cancer Arm</arm_group_label>
    <description>Participants with new diagnosis of hepatobiliary malignancies, from whom blood samples will be collected</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Benign Diseases Arm</arm_group_label>
    <description>Participants with benign diseases of the hepatobiliary system, from whom blood samples will be collected</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Multi-cancer early detection test</intervention_name>
    <description>Blood collection and multi-cancer early detection testing</description>
    <arm_group_label>Benign Diseases Arm</arm_group_label>
    <arm_group_label>Cancer Arm</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Eligible participants will be recruited from medical centers and assigned into two arms,&#xD;
        including participants with new diagnosis of hepatobiliary malignancies and benign diseases&#xD;
        of the hepatobiliary system.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria for All the Participants:&#xD;
&#xD;
          -  40-75 years old&#xD;
&#xD;
          -  Ability to comply with study procedures&#xD;
&#xD;
          -  Ability to provide a written informed consent&#xD;
&#xD;
        Exclusion Criteria for All the Participants:&#xD;
&#xD;
          -  Pregnancy or lactating women&#xD;
&#xD;
          -  Recipients of organ transplant or prior non-autologous (allogeneic) bone marrow&#xD;
             transplant or stem cell transplant&#xD;
&#xD;
          -  Recipients of blood transfusion within 7 days prior to study blood draw&#xD;
&#xD;
          -  Recipients of anti-microbial therapy within 14 days prior to study blood draw&#xD;
&#xD;
          -  Recipients of any anti-cancer therapy within 30 days prior to study blood draw, due to&#xD;
             diseases other than cancer&#xD;
&#xD;
        Inclusion Criteria for Cancer Arm Participants:&#xD;
&#xD;
          -  Confirmed diagnosis or highly suspicious cases of hepatobiliary malignancies&#xD;
&#xD;
          -  No prior or ongoing anti-cancer therapy (local or systematic) prior to study blood&#xD;
             draw&#xD;
&#xD;
        Exclusion Criteria for Cancer Arm Participants:&#xD;
&#xD;
          -  Current diagnosis of other malignancies or multiple primary tumors&#xD;
&#xD;
          -  Diagnosis of benign diseases by histopathological assessments&#xD;
&#xD;
          -  Inability to characterize whether the lesion is malignant or benign&#xD;
&#xD;
          -  Prior or ongoing treatment of cancer&#xD;
&#xD;
        Inclusion Criteria for Benign Diseases Arm Participants:&#xD;
&#xD;
          -  Confirmed diagnosis of benign diseases of the hepatobiliary system&#xD;
&#xD;
          -  No prior radical treatment of the benign diseases prior to study blood draw&#xD;
&#xD;
        Exclusion Criteria for Benign Diseases Arm Participants:&#xD;
&#xD;
          -  Current or history of malignancies or precancerous lesions&#xD;
&#xD;
          -  No confirmed diagnosis or inability to characterize a benign disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mingxin Pan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhujiang Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mingxin Pan, M.D.</last_name>
    <phone>+86-020-62782562</phone>
    <email>pmxwxy@sohu.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhujiang Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510280</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mingxin Pan, M.D.</last_name>
      <phone>+86-020-62782562</phone>
      <email>pmxwxy@sohu.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 6, 2021</study_first_submitted>
  <study_first_submitted_qc>April 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2021</study_first_posted>
  <last_update_submitted>April 6, 2021</last_update_submitted>
  <last_update_submitted_qc>April 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatobiliary malignancies</keyword>
  <keyword>Liquid biopsy</keyword>
  <keyword>Cell-free DNA</keyword>
  <keyword>Early detection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

